Preston Wendell Wells Sells 165 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Stock Up 2.2%

NYSE:SYK opened at $368.35 on Friday. The firm has a market capitalization of $140.87 billion, a PE ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a 50 day moving average of $369.38 and a 200-day moving average of $380.68.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the firm posted $2.87 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $448.00 target price on shares of Stryker in a research note on Friday, November 14th. Barclays boosted their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Truist Financial raised their price target on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a report on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Hedge Funds Weigh In On Stryker

Several large investors have recently made changes to their positions in the business. Consolidated Portfolio Review Corp lifted its stake in Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after purchasing an additional 26 shares during the last quarter. Princeton Global Asset Management LLC increased its holdings in shares of Stryker by 16.9% in the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after buying an additional 26 shares in the last quarter. Sunflower Bank N.A. increased its holdings in shares of Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC lifted its position in shares of Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after acquiring an additional 27 shares during the last quarter. Finally, Sachetta LLC boosted its stake in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.